ARTICLE
|
doi:10.20944/preprints202306.0341.v1
Subject:
Medicine And Pharmacology,
Epidemiology And Infectious Diseases
Keywords:
tuberculosis infection; tuberculosis disease; tuberculosis preventive treatment; latent tuberculosis infection; diabetes mellitus; adverse events; isoniazid; rifampicin; randomized controlled trial
Online: 5 June 2023 (15:01:24 CEST)